Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms

 
• By Jessica Merrill
flashing light
Pfizer's Xeljanz shows safety issues in a new study • Source: Shutterstock

More from Immunological

More from Therapeutic Category